This Project Grant award of $471,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The funding supports research by The Cleveland Clinic Foundation to develop next-generation prostate cancer therapeutics by exploiting the allosteric regulation of the androgen receptor. The award period is from September 1, 2023 to August 31, 2025. As a prime recipient of federal grants, The Cleveland Clinic Foundation has a history of receiving funding from the Department of Health and Human Services, Defense Health Agency, and other agencies to investigate medical treatments and solutions for public health needs.
Generated 4/23/24, 6:20 AM